News
AMRN
10.57
-6.13%
-0.69
Amarin Corporation plc Reports Resignation of Director Patrice Bonfiglio Effective November 16, 2026
NASDAQ · 1d ago
Amarin Reports Immediate Resignation of Company Director
TipRanks · 2d ago
Weekly Report: what happened at AMRN last week (1109-1113)?
Weekly Report · 4d ago
Amarin presents REDUCE-IT data on lipoprotein link to cardiovascular risk
TipRanks · 11/09 14:21
Amarin Presents New Clinical Data Evaluating Lipoprotein(A) And Other apoB Containing Lipoproteins As Predictors Of MACE, At AHA Scientific Sessions 2026
Benzinga · 11/09 13:09
Weekly Report: what happened at AMRN last week (1102-1106)?
Weekly Report · 11/09 09:22
Weekly Report: what happened at AMRN last week (1026-1030)?
Weekly Report · 11/02 09:22
Amarin (AMRN) Q3 Earnings Reveal A Profit Turn Built On Cost Cuts
Simply Wall St · 10/29 22:40
Amarin Corporation plc Reports Q3 2026 Financial Results
NASDAQ · 10/28 15:52
What Amarin (AMRN) Said on Its Q3 Earnings Call
NASDAQ · 10/28 14:04
Amarin Corp Q3 2026 Earnings Call Transcript
Benzinga · 10/28 12:35
Amarin’s Q3 revenue drops amid U.S. pricing pressure
Seeking Alpha · 10/28 11:04
Here are the major earnings before the open Wednesday
Seeking Alpha · 10/27 22:00
At a glance: stocks gapping up premarket
Seeking Alpha · 10/26 10:55
Weekly Report: what happened at AMRN last week (1019-1023)?
Weekly Report · 10/26 09:21
Weekend Fly By: Top five stock stories
TipRanks · 10/26 00:10
Amarin announces EPA for Metastasis Trial 2 did not meet primary endpoint
TipRanks · 10/25 20:35
Earnings Week Ahead: MSFT, GOOGL, AMZN, XOM, BA, VZ, and more
Seeking Alpha · 10/25 12:07
Weekly Report: what happened at AMRN last week (1012-1016)?
Weekly Report · 10/19 09:22
Weekly Report: what happened at AMRN last week (1005-1009)?
Weekly Report · 10/12 09:23
More
Webull provides a variety of real-time AMRN stock news. You can receive the latest news about Amarin through multiple platforms. This information may help you make smarter investment decisions.
About AMRN
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.